BR0009791A - Métodos para modular, para potencializar e para regular para baixo uma resposta imune de tipo 1 em um paciente, para acentuar a produção de uma citoquina associada com resposta imune de tipo 1, para regular para baixo a produção de uma citoquina associada com resposta imune de tipo 2, para estimular produção de interleucina-12 (il-12) por um macrófago, para inibir a produção de interleucina-10 (il-10) por um macrófago, para a produção de uma molécula, imunomoduladora, e para modular uma resposta imune em uma célula, células de tumor modificadas, e hospedeira, moléculas imunomoduladora biossintética, e de ácido nucleico isolada, vetor de expressão, e, composição farmacêutica - Google Patents

Métodos para modular, para potencializar e para regular para baixo uma resposta imune de tipo 1 em um paciente, para acentuar a produção de uma citoquina associada com resposta imune de tipo 1, para regular para baixo a produção de uma citoquina associada com resposta imune de tipo 2, para estimular produção de interleucina-12 (il-12) por um macrófago, para inibir a produção de interleucina-10 (il-10) por um macrófago, para a produção de uma molécula, imunomoduladora, e para modular uma resposta imune em uma célula, células de tumor modificadas, e hospedeira, moléculas imunomoduladora biossintética, e de ácido nucleico isolada, vetor de expressão, e, composição farmacêutica

Info

Publication number
BR0009791A
BR0009791A BR0009791-8A BR0009791A BR0009791A BR 0009791 A BR0009791 A BR 0009791A BR 0009791 A BR0009791 A BR 0009791A BR 0009791 A BR0009791 A BR 0009791A
Authority
BR
Brazil
Prior art keywords
production
type
immune response
response
modulate
Prior art date
Application number
BR0009791-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Samy Ashkar
Georg Weber
Melvyn Glimcher
Harvey Cantor
Original Assignee
Childrens Medical Center
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Dana Farber Cancer Inst Inc filed Critical Childrens Medical Center
Publication of BR0009791A publication Critical patent/BR0009791A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
BR0009791-8A 1999-04-15 2000-04-17 Métodos para modular, para potencializar e para regular para baixo uma resposta imune de tipo 1 em um paciente, para acentuar a produção de uma citoquina associada com resposta imune de tipo 1, para regular para baixo a produção de uma citoquina associada com resposta imune de tipo 2, para estimular produção de interleucina-12 (il-12) por um macrófago, para inibir a produção de interleucina-10 (il-10) por um macrófago, para a produção de uma molécula, imunomoduladora, e para modular uma resposta imune em uma célula, células de tumor modificadas, e hospedeira, moléculas imunomoduladora biossintética, e de ácido nucleico isolada, vetor de expressão, e, composição farmacêutica BR0009791A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12977299P 1999-04-15 1999-04-15
PCT/US2000/010340 WO2000063241A2 (fr) 1999-04-15 2000-04-17 Procedes et compositions de modulation d'une reponse immunitaire

Publications (1)

Publication Number Publication Date
BR0009791A true BR0009791A (pt) 2002-01-08

Family

ID=22441531

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009791-8A BR0009791A (pt) 1999-04-15 2000-04-17 Métodos para modular, para potencializar e para regular para baixo uma resposta imune de tipo 1 em um paciente, para acentuar a produção de uma citoquina associada com resposta imune de tipo 1, para regular para baixo a produção de uma citoquina associada com resposta imune de tipo 2, para estimular produção de interleucina-12 (il-12) por um macrófago, para inibir a produção de interleucina-10 (il-10) por um macrófago, para a produção de uma molécula, imunomoduladora, e para modular uma resposta imune em uma célula, células de tumor modificadas, e hospedeira, moléculas imunomoduladora biossintética, e de ácido nucleico isolada, vetor de expressão, e, composição farmacêutica

Country Status (8)

Country Link
EP (1) EP1175223A2 (fr)
JP (1) JP2003517284A (fr)
AU (1) AU773350B2 (fr)
BR (1) BR0009791A (fr)
CA (1) CA2370129A1 (fr)
IL (1) IL145891A0 (fr)
MX (1) MXPA01010332A (fr)
WO (1) WO2000063241A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0101973D0 (en) * 2001-01-25 2001-03-14 Statens Seruminstitut Improved in vitro diagnostic method of detecting a cell-mediated immune response
JP2002221520A (ja) * 2001-01-29 2002-08-09 Sumitomo Chem Co Ltd 免疫型の予測方法
WO2002090974A2 (fr) * 2001-05-09 2002-11-14 Biovision Ag Procede pour depister une maladie dementielle chronique evolutive, et peptides et reactifs de depistage associes
EA006655B1 (ru) * 2001-05-17 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
GB0116185D0 (en) * 2001-07-02 2001-08-22 Imp College Innovations Ltd Substances
WO2003027151A1 (fr) 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Anticorps recombinant anti-osteopontine et son utilisation
CA2489905A1 (fr) * 2002-06-25 2003-12-31 Aventis Pharmaceuticals Inc. Osteopontine, oligodendrocytes et myelinisation
US7678889B2 (en) 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
EP1637159A4 (fr) * 2003-05-23 2009-01-21 Immuno Biological Lab Co Ltd Inhibiteur d'activation cellulaire immunocompetente et son utilisation
WO2005100562A1 (fr) * 2004-04-12 2005-10-27 Gene Techno Science Co., Ltd. ARNsi POUR L'OSTÉOPONTINE
JP5399710B2 (ja) * 2006-10-26 2014-01-29 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに対する抗体およびその製法と用途
CN101293916A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
CN104530233B (zh) 2008-04-24 2018-01-30 株式会社遗传科技 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
US20110092575A1 (en) * 2008-06-06 2011-04-21 Assignment for Published Patent Application Gene Techno Science Co., Ltd. Sirna of human osteopontin
EP2480665A4 (fr) 2009-09-24 2013-04-03 Gene Techno Science Co Ltd Anticorps humanisés spécifiques d'une séquence rgd d'acides aminés d'une protéine matricielle extracellulaire et leurs utilisations
WO2013086459A1 (fr) * 2011-12-07 2013-06-13 Arla Foods Amba Variantes d'ostéopontine destinées à être utilisées dans la suppression ou la prévention de la croissance tumorale, et compositions les contenant
AU2014286123B2 (en) 2013-07-05 2019-02-28 Arla Foods Amba Mammalian milk osteopontin for enhancing immune responsiveness
US10512673B2 (en) 2015-01-07 2019-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease
CN112040973B (zh) 2018-04-25 2022-03-29 合生元（广州）健康产品有限公司 用作药物的骨桥蛋白和2’-岩藻糖基乳糖的组合
CA3216462A1 (fr) * 2021-04-20 2022-10-27 University Of Cincinnati Adjuvant vaccinal pour maladies infectieuses
CN115707772A (zh) * 2021-08-18 2023-02-21 澳门大学 一种诱导剂、巨噬细胞及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (fr) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research Procede utilisant l'osteopontine pour moduler une reponse immunitaire

Also Published As

Publication number Publication date
CA2370129A1 (fr) 2000-10-26
JP2003517284A (ja) 2003-05-27
IL145891A0 (en) 2002-07-25
WO2000063241A3 (fr) 2001-05-10
EP1175223A2 (fr) 2002-01-30
AU773350B2 (en) 2004-05-20
AU4357500A (en) 2000-11-02
WO2000063241A2 (fr) 2000-10-26
MXPA01010332A (es) 2002-09-18
WO2000063241A9 (fr) 2002-03-28

Similar Documents

Publication Publication Date Title
BR0009791A (pt) Métodos para modular, para potencializar e para regular para baixo uma resposta imune de tipo 1 em um paciente, para acentuar a produção de uma citoquina associada com resposta imune de tipo 1, para regular para baixo a produção de uma citoquina associada com resposta imune de tipo 2, para estimular produção de interleucina-12 (il-12) por um macrófago, para inibir a produção de interleucina-10 (il-10) por um macrófago, para a produção de uma molécula, imunomoduladora, e para modular uma resposta imune em uma célula, células de tumor modificadas, e hospedeira, moléculas imunomoduladora biossintética, e de ácido nucleico isolada, vetor de expressão, e, composição farmacêutica
Han et al. Characteristic immunostimulation by angelan isolated from Angelica gigas Nakai
HUP0203084A2 (en) Use of baff receptor (bcma) as an immunoregulatory agent
Vandermeulen et al. Optimisation of intradermal DNA electrotransfer for immunisation
GEP20002180B (en) Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
DK0730601T3 (da) Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner
CY1105949T1 (el) Νευροτροφικος αυξητικος παραγοντας
AU3368497A (en) Human dnase i hyperactive variants
ATE375094T1 (de) Von menschen oder tieren verwenbare diätetische und/oder pharmazeutische zubereitungen, auf basis von probiotischen mikroorganismen
BR0210225A (pt) Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante
ATE370749T1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
BRPI0010612B8 (pt) vacinas
BRPI0508424A (pt) muteìnas de interleucina-2 melhoradas
WO1998019167A3 (fr) Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule
WO2007049400A1 (fr) Composition favorisant la production de collagene et/ou d’acide hyaluronique
ATE413208T1 (de) Kosmetische zusammensetzung enhaltend mindestens ein silikon/acrylat copolymer und mindestens ein nichtzellulosiches verdickungsmittel
GEP20032988B (en) Immunostimulatory and Metastasis Inhibiting Fermented Vegetal Material, Pharmaceutical Compositions and Use Thereof
NZ297529A (en) Two component pharmaceutical system comprising a targeting moiety linked to a mutated enzyme
BR0314893A (pt) Vetor para vacina contra hpv e microrganismo transformado pelo vetor
IL99778A0 (en) Compositions for the treatment of cell proliferation disorders
ZA895840B (en) N-2,3-butadienyl tri-and tetraaminoalkane derivatives
MX9805300A (es) Acidos nucleicos que codifican factor-2 inductor de interferon gama.
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
FR2798844B1 (fr) Composition cosmetique comprenant au moins un copolymere silicone/acrylate et au moins un polymere silicone greffe
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTA A 6A, 7A 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.